Legal Representation
Attorney
David W. Staple
USPTO Deadlines
Next Deadline
1686 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-03-12)
Due Date
March 12, 2030
Grace Period Ends
September 12, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
44 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 12, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Mar 12, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Feb 2, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Feb 1, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jan 11, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jan 5, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jan 5, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Jul 11, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 10, 2023 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Jul 10, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 29, 2023 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Jun 29, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 6, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 4, 2023 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| Jan 4, 2023 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| Jan 4, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 28, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 24, 2022 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 24, 2022 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jun 24, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 21, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 19, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jan 19, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jan 19, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 11, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 11, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 11, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jul 22, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 20, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jul 20, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jul 20, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 26, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 1, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 1, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 11, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 23, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 22, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 22, 2020 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 22, 2020 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 22, 2020 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 22, 2020 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 21, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 19, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 24, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
oligonucleotide preparations for therapeutic pharmaceutical purposes for a wide variety of conditions
First Use Anywhere:
Dec 7, 2023
First Use in Commerce:
Dec 7, 2023
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"